Mon, May 20, 2024
In press (Jan-Feb)
Back to the articles list |
Back to browse issues page
1- Department of Pathology, Smt Kashibai Navale Medical College, Pune, India
2- Department of Pathology, Smt NHL Municipal Medical College, Ahmedabad, India , anjali@knee.in
3- Department of Pathology, GMERS Medical College, Palanpur, India
2- Department of Pathology, Smt NHL Municipal Medical College, Ahmedabad, India , anjali@knee.in
3- Department of Pathology, GMERS Medical College, Palanpur, India
Abstract: (216 Views)
Background: A higher occurrence of raised homocysteine levels has been reported in individuals with type 2 diabetes (T2D), particularly those with macroangiopathy and nephropathy. Given that hyperhomocysteinemia is a risk factor for T2D, mitigating this condition could potentially benefit T2D patients. This study aimed to investigate the influence of homocysteine on T2D and cardiovascular disease (CVD), as well as the factors that modify homocysteine levels.
Methods: This cross sectional, observational study was conducted on 122 individuals in a tertiary care center in Western India. Data related to anthropometry, demography, and biochemistry were gathered following established standards. Statistical analysis was performed using Chi-square test. A P-value of <0.05 was considered statistically significant.
Results: The findings indicated a significantly larger percentage of hyperhomocysteinemia in males, smokers, and individuals with elevated fasting blood sugar and HbA1c levels. The proportion of subjects with high homocysteine levels was notably greater in those with high total cholesterol and triglyceride levels. A significant correlation was observed between increased serum homocysteine levels and decreased serum folic acid and vitamin B12 levels in patients with ischemic heart disease.
Conclusion: Elevated homocysteine levels are observed in smokers and diabetic patients, potentially leading to CVD. Furthermore, this study found a correlation between an increase in serum homocysteine levels and a decrease in serum folic acid and vitamin B12 levels in patients with ischemic heart disease.
Methods: This cross sectional, observational study was conducted on 122 individuals in a tertiary care center in Western India. Data related to anthropometry, demography, and biochemistry were gathered following established standards. Statistical analysis was performed using Chi-square test. A P-value of <0.05 was considered statistically significant.
Results: The findings indicated a significantly larger percentage of hyperhomocysteinemia in males, smokers, and individuals with elevated fasting blood sugar and HbA1c levels. The proportion of subjects with high homocysteine levels was notably greater in those with high total cholesterol and triglyceride levels. A significant correlation was observed between increased serum homocysteine levels and decreased serum folic acid and vitamin B12 levels in patients with ischemic heart disease.
Conclusion: Elevated homocysteine levels are observed in smokers and diabetic patients, potentially leading to CVD. Furthermore, this study found a correlation between an increase in serum homocysteine levels and a decrease in serum folic acid and vitamin B12 levels in patients with ischemic heart disease.
Research Article: Original Paper |
Subject:
Pathology
Received: 2022/07/10 | Accepted: 2024/01/24 | Published: 2024/01/11 | ePublished: 2024/01/11
Received: 2022/07/10 | Accepted: 2024/01/24 | Published: 2024/01/11 | ePublished: 2024/01/11
References
1. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr. 1992;55(1):131-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. McCully KS. Vascular pathology of homocysteinemia : implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111-28. [View at Publisher] [PMID] [Google Scholar]
3. Maron B, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med. 2009;60:39-54. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Al-Obaidi M, Stubbs P, Amersey R, Noble M. Acute and convalescent changes in plasma homocysteine concentrations in acute coronary syndromes. Heart. 2001;85(4):380-4. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Qi X, Li L, Yang G, Liu J, Li K, Tang Y, et al. Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2007;66(4):593-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Brosnan JT. Homocysteine and cardiovascular disease: interactions between nutrition, genetics and lifestyle. Can J Appl Physiol. 2004;29(6):773-80. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Signorello MG, Viviani GL, Armani U, R cerone, G Minniti. Homocysteine, reactive oxygen species and nitric oxide in type 2 diabetes mellitus.Thromb Res. 2007;120(4):607-13. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Debra Manzella RN. Kidney disease in diabetes. 2008. [View at Publisher] [Google Scholar]
9. Weir CB, Jan A. BMI classification percentile and cut off points. Treasure Island: StatPearls; 2020. [View at Publisher] [PMID] [Google Scholar]
10. Macko RF, Kittner SJ, Ivey FM, Epstein A, Sparks MJ, Hebel JR, et al. Effects of vitamin therapy on plasma total homocysteine, endothelial injury markers, and fibrinolysis in stroke patients. J Stroke Cerebrovasc Dis. 2002;11(1):1-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Ganji V, Kafai MR. Demographic, lifestyle and health characteristics and serum vitamin status are the determinants of plasma total homocysteine concentration in the post -folic acid fortification period, 1999-2004. J Nutr. 2009;139(2):345-52. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Drzewoski J, Czupryniak L, Chwatko G, Bald E. Hyperhomocysteinemia in poorly controlled type 2 diabetes patients. Diabetes Nutr Metab. 2000;13(6):319-24. [View at Publisher] [PMID] [Google Scholar]
13. Cho EH, Kim EH, Kim WG, Jeong EH, Koh EH, Lee WJ, et al. Homocysteine as a Risk Factor for Development of Microalbuminuria in Type 2 Diabetes. Korean Diabetes J. 2010;34(3):200-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Nada S, Abdul Jalil F. Serum levels of Interleukin 6 and Homocysteine in Type 2 Diabetic Patients with renal failure complication. Karbala J Med. 2010;3(1-6):804-11. [View at Publisher] [Google Scholar]
15. Shaikh MK, Devrajani BR, Shaikh A, Ali Shah SZ, Shaikh S, Singh D. Plasma Homocysteine Level in Patients with Diabetes mellitus. World Applied Sciences Journal. 2012;16(9):1269-73. [View at Publisher] [Google Scholar]
16. Okumura K, Aso Y. High Plasma Homocysteine Concentrations Are Associated With Plasma Concentrations of Thrombomodulin in Patients with Type 2 Diabetes and Link Diabetic Nephropathy to Macroangiopathy. Metabolism. 2003;52(11):1517-22. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Anand P, Awasthi S, Mahdi A, Tiwari M, Agarwal GG. Serum Homocysteine in Indian Adolescents. Indian Journal of Pediatrics. 2009;76(6):705-9. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. El Oudi M, Aouni Z, Mazigh C, Machghoul S. Total homocysteine levels and cardiovascular risk factors in healthy Tunisians. East Mediterr Health J. 2011;17(12):937-42. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Mcneely MD. Folic acid. In: Presce AJ, Kaplan LA, editors. Methods in clinical chemistry. St Louis, CV Mosby; 1987. p.539542. [View at Publisher]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.